Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL

NEW YORK, March 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

CR Bard Inc. Analyst Notes 

On March 25, 2014, CR Bard Inc. (CR Bard) announced that it will present at the Needham Healthcare Conference in New York City on April 8, 2014. As stated by the Company, Timothy M. Ring, Chairman and CEO, will discuss the Company in a presentation scheduled to begin at 8:00 a.m. EDT. According to CR Bard, a live webcast of the presentation as well as question and answer session will be accessible to all investors through Bard's website at http://investorrelations.crbard.com. The webcast will also be available on the website for future on-demand replay. The full analyst notes on CR Bard Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/BCR/report.pdf

--

Medivation, Inc. Analyst Notes 

On March 18, 2014, Medivation, Inc. (Medivation), together with Astellas Pharma Inc. (Astellas Pharma), announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. According to the Companies, the sNDA application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-naïve mCRPC patients and that the marketing authorization application is expected to be submitted to the European Medicines Agency later this year. The full analyst notes on Medivation, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/MDVN/report.pdf

--

Align Technology Inc. Analyst Notes 

On March 21, 2014, Align Technology Inc. (Align) announced that the International Trade Commission (ITC) extended the target date for completion of its review of the Initial Determination in the ClearCorrect investigation. The new target date is April 3, 2014. Align stated that although the Commission did not indicate the reason for the extension, the fact that the Commission received significant public comment could explain the brief further delay. The Company first filed an ITC complaint against ClearCorrect on March 1, 2012, asserting that ClearCorrect's aligners are made using digital data and treatment plans imported from Pakistan that infringe Align's patents. Align also has a patent infringement action pending against ClearCorrect in the United States District Court for the Southern District of Texas alleging infringement of nine Align patents, including four additional patents not included in the ITC litigation. The full analyst notes on Align Technology Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/ALGN/report.pdf

--

Covance Inc. Analyst Notes 

On March 25, 2014, Covance Inc. (Covance) announced that it is building on its expertise in biologics development with new investments to meet growing client demand, including the expansion of its global bioanalytical footprint and the addition of scientific leaders to its biologics team. "Our new biologics solutions will enable us to work in closer collaboration with our clients, providing them actionable insights to help expedite their large molecule development," said Deborah Keller, Executive Vice President, R&D Laboratories, Covance. Ms. Keller also added, "Doubling our large molecule capacity and enhancing a leading team with additional dedicated scientific experts with proven success in managing through these complexities will further strengthen our leadership position in a growing market." The full analyst notes on Covance Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/CVD/report.pdf

--

PAREXEL International Corporation Analyst Notes 

On March 19, 2014, PAREXEL International Corporation (PAREXEL) announced the expansion of its global Clinical Logistics Services (CLS) capabilities. As stated by the Company, a new, state-of-the-art distribution center in Singapore and the recent expansion of the Company's facilities in Billerica, Massachusetts, will help PAREXEL more effectively manage clients' global clinical trial supply requirements. "As clinical trials increase in size and complexity, clients are challenged to develop and implement strategies that create consistent sourcing, manufacturing, storage and distribution processes along the supply chain," said Mark A. Goldberg, President and Chief Operating Officer. "Our investments in these important distribution centers and depots are part of the Company's ongoing efforts to simplify the clinical trial journey for biopharmaceutical clients by supporting their growing global supply and logistics needs," Mr. Goldberg further added. The full analyst notes on PAREXEL International Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03282014/PRXL/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review